Yuji Shimura, Hirohiko Shibayama, Aya Nakaya, Ryosuke Yamamura, Kazunori Imada, Hitomi Kaneko, Hitoshi Hanamoto, Shin-Ichi Fuchida, Hirokazu Tanaka, Satoru Kosugi, Miki Kiyota, Toshimitsu Matsui, Junya Kanda, Masato Iida, Mitsuhiro Matsuda, Nobuhiko Uoshima, Masaru Shibano, Takahiro Karasuno, Tsuneyoshi Hamada, Kensuke Ohta, Tomoki Ito, Hideo Yagi, Satoshi Yoshihara, Chihiro Shimazaki, Shosaku Nomura, Masayuki Hino, Akifumi Takaori-Kondo, Itaru Matsumura, Yuzuru Kanakura, Junya Kuroda
To investigate the real-world clinical outcomes and management of novel drug-containing therapies for newly diagnosed multiple myeloma (MM) patients, we retrospectively analyzed data on the first-line treatment for newly diagnosed transplant-ineligible MM patients from Kansai Myeloma Forum, a registry network in Japan. A total of 598 patients treated with novel drugs between March 2007 and February 2018 were analyzed. Regimens used were VD (n = 305), Rd (n = 103), VMP (n = 97), VCD (n = 71), and VRd (n = 22)...
September 5, 2023: International Journal of Hematology